The precursor of
matrix metalloproteinase 9 (pro-MMP-9, progelatinase B) noncovalently binds to
tissue inhibitor of metalloproteinases (TIMP)-1 through the C-terminal domain of each molecule. We have isolated the proMMP-9.TIMP-1 complex from the medium of human
fibrosarcoma HT-1080 cells and investigated the activation processes of the complex by
4-aminophenylmercuric acetate,
trypsin, and
matrix metalloproteinase 3 (
MMP-3,
stromelysin 1). The treatment of the proMMP-9.TIMP-1 complex with
4-aminophenylmercuric acetate or
trypsin converts
proMMP-9 to lower molecular weight species corresponding to active forms, but no gelatinolytic activity is detected. The lack of enzymic activity results from binding of
TIMP-1 to the activated MMP-9. The treatment of the proMMP-9.TIMP-1 complex with a possible physiological
proMMP-9 activator, MMP-3, does not reveal any gelatinolytic activity unless the molar ratio of MMP-3 to the complex exceeds 1. This is due to the inhibition of MMP-3 by
TIMP-1 forming a ternary proMMP-9.TIMP-1.MMP-3 complex. The formation of the ternary complex weakens the interaction between
proMMP-9 and
TIMP-1, resulting in partial dissociation of the complex into
proMMP-9 and the TIMP-1.MMP-3 complex. When MMP-3 is in excess, the propeptide is completely processed, and the full activity of MMP-9 is detected. Similarly, the proMMP-9.TIMP-1 complex inhibits MMP-1 (
interstitial collagenase) and in turn renders the
proMMP-9 activable by a catalytic amount of MMP-3. These results suggest that formation of the proMMP-9.TIMP-1 complex regulates extracellular matrix breakdown in tissue by switching the predominant
MMP activity from one type to another.